The aim of the fund is to generate an average annual return of at least 12%, which places high demands on the knowledge and experience of the Investment Team.
OUR INVESTMENT TEAM MEMBERS HAVE LONG EXPERIENCE…
Henrik Rhenman and Ellinor Hult are responsible for the portfolio management. Henrik is a biochemist by training and has over 30 years of asset management experience within the healthcare sector, based both in Sweden and the US. The tremendous success of the fund depends largely on his skills and the unique approach he has developed. Ellinor has a B.Sc., with 10 years of experience in the stock market.
…AND A UNIQUE WAY OF WORKING
A major contributing factor to the fund’s outstanding success is the collaboration between the Investment Taam and our Scientific Advisory Board. Professor Sten Nilsson is the Board’s chairman, and its members are well-established, practising medical experts with an extensive network of researchers and specialists worldwide. Access to the members’ medical expertise gives the Investment Team unique insights and understanding of such areas as clinical trials, new drugs, new technologies and methods of treatments, and thus provides an invaluable basis for their investment decisions.
This highly successful approach was first established by Henrik Rhenman during the late 90’s when he started a global healthcare fund for his employer. During his ten-year tenure as Chief Investment Officer between 1998 and 2008, the fund increased in value by 799% (in USD). It thus became the world’s best pharmaceutical fund (according to Bloomberg’s database). During the same period a global index rose by only 40%.
Biochemist, Royal Institute of Technology, Bachelor of Science, Stockholm School of Economics. Founder and Chief Investment Officer, Rhenman & Partners. Former Founder & CIO, Carnegie Healthcare Funds, Carnegie Investment Bank. Managing Director, Portfolio Manager, SG Cowen, Boston. Portfolio Manager, SEB Pharmaceutical Fund. Chief Analyst, Hagströmer & Qviberg
Total number of board appointments: 2
SENIOR ANALYST HEALTHCARE STOCK SELECTION
Employed at Rhenman & Partners since: 2012
Ten years of experience in the global stock market
2011–2012 Vice President, Non-Japan Asian Equity Sales, Samsung Securities, London
2006–2011 Vice President, Non-Japan Asian Equity Sales, Credit Suisse, London
Education: B.Sc. Stockholm School of Economics